Zai Lab (Zai Lab) EBIT per Share : $-3.87 (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Zai Lab EBIT per Share?

Zai Lab's EBIT per Share for the three months ended in Dec. 2023 was $-1.25. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.87.

During the past 3 years, the average EBIT per Share Growth Rate was 0.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Zai Lab's EBIT per Share or its related term are showing as below:

ZLAB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -101 Med: -29.35 Max: 0.1
Current: 0.1

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Zai Lab was 0.10% per year. The lowest was -101.00% per year. And the median was -29.35% per year.

ZLAB's 3-Year EBIT Growth Rate is ranked worse than
54.56% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs ZLAB: 0.10

Zai Lab's EBIT for the three months ended in Dec. 2023 was $-121.5 Mil.

Zai Lab EBIT per Share Historical Data

The historical data trend for Zai Lab's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab EBIT per Share Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-3.01

-3.45

-7.48

-4.10

-3.87

Zai Lab Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.89	-0.72	-1.03	-0.86	-1.25

Zai Lab EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Zai Lab's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-374.14	/	96.639
=	-3.87

Zai Lab's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-121.548	/	97.039
=	-1.25

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.87

Zai Lab (NAS:ZLAB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Zai Lab EBIT per Share Related Terms

Thank you for viewing the detailed overview of Zai Lab's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab (Zai Lab) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ZLAB:Mexico 09688:Hong Kong 1ZLB:Germany 1ZLB:Germany 1ZL:Germany 1ZL:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Harald Reinhart	officer: Chief Medical Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Edmondson Frazor Titus Iii	officer: Chief Legal Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Ying Du	director, officer: Chairwoman & CEO	C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Rafael Amado	officer: See Remarks	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Joshua L Smiley	officer: Chief Operating Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen	officer: Chief Financial Officer	314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth	director	37 HANCOCK STREET, BOSTON MA 02114
John D Diekman	director	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Tao Fu	director, officer: President & COO	3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul	officer: Chief Financial Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen	director	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210